Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of the direct oral anticoagulants for prevention of left ventricular thrombus after anterior acute myocardial infarction (APERITIF) trial.
Puymirat E, Soulat G, Fayol A, Mousseaux E, Montalescot G, Cayla G, Steg PG, Berard L, Rousseau A, Drouet É, Simon T, Danchin N; APERITIF study investigators. Puymirat E, et al. Among authors: montalescot g. Am Heart J. 2023 Dec;266:98-105. doi: 10.1016/j.ahj.2023.09.005. Epub 2023 Sep 14. Am Heart J. 2023. PMID: 37716448 Clinical Trial.
Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study).
Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Randé JL, Henry P, Steg PG, Michel PL, Allouch P, Cohen A, Colin P, Durand E, Montalescot G; SYCOMORE Investigators. Dumaine R, et al. Among authors: montalescot g. Am J Cardiol. 2004 Dec 15;94(12):1543-7. doi: 10.1016/j.amjcard.2004.08.035. Am J Cardiol. 2004. PMID: 15589013
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. Giugliano RP, et al. Among authors: montalescot g. Am Heart J. 2005 Jun;149(6):994-1002. doi: 10.1016/j.ahj.2005.03.029. Am Heart J. 2005. PMID: 15976780
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: montalescot g. Am Heart J. 2005 Sep;150(3):401. doi: 10.1016/j.ahj.2005.03.017. Am Heart J. 2005. PMID: 16169314 Clinical Trial.
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).
Goodman SG, Steg PG, Eagle KA, Fox KA, López-Sendón J, Montalescot G, Budaj A, Kennelly BM, Gore JM, Allegrone J, Granger CB, Gurfinkel EP; GRACE Investigators. Goodman SG, et al. Among authors: montalescot g. Am Heart J. 2006 Mar;151(3):654-60. doi: 10.1016/j.ahj.2005.05.014. Am Heart J. 2006. PMID: 16504627
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Montalescot G, et al. N Engl J Med. 2006 Sep 7;355(10):1006-17. doi: 10.1056/NEJMoa052711. N Engl J Med. 2006. PMID: 16957147 Free article. Clinical Trial.
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Wiviott SD, et al. Among authors: montalescot g. Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012. Am Heart J. 2006. PMID: 16996826 Clinical Trial.
813 results